Stockscreener 앱 받기
1.415
0.70%
0.005
Outlook Therapeutics Inc 주식(OTLK)의 최신 뉴스
Outlook Therapeutics(OTLK) Stock Options Chain | Quotes & News - Moomoo
Outlook Therapeutics files dispute resolution request with FDA - Investing.com
Enterprise value to revenue forward of Outlook Therapeutics, Inc. – NASDAQ:OTLK - TradingView
Why Is OTLK Stock Falling Today? - Stocktwits
OTLK Stock Soars 28% After FDA Sets July Date For Lytenava Decision - Stocktwits
Outlook Therapeutics Stock (OTLK) Opinions on FDA Review for Lytenava - Quiver Quantitative
Outlook Therapeutics Regains Nasdaq Compliance - marketscreener.com
symbol__ Stock Quote Price and Forecast - CNN
Outlook Therapeutics Regains Nasdaq Minimum Bid Compliance - The Globe and Mail
OTLKOutlook Therapeutics Inc Latest SEC Filings - Finviz
Outlook Therapeutics (OTLK) Regains Compliance with Nasdaq Minimum Bid Price Requirement – 8-K Filing June 2026 – Minichart - Minichart
Outlook Therapeutics Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Outlook Therapeutics (OTLK) restores Nasdaq minimum bid compliance, delisting threat closed - Stock Titan
OTLK Stock Climbs As FDA Fast-Tracks Lytenava Decision - StocksToTrade
Enterprise value to EBITDA forward of Outlook Therapeutics, Inc. – NASDAQ:OTLK - TradingView
Outlook Therapeutics, Inc. Actuals & Estimates (NASDAQ:OTLK) - TradingView
OTLK stock up 35% as FDA accepts resubmitted eye drug BLA for review - MSN
Outlook Therapeutics, Inc. Actuals & Estimates (FWB:41O) - TradingView
Enterprise value to revenue forward of Outlook Therapeutics, Inc. – MUN:41O - TradingView
Price to sales forward of Outlook Therapeutics, Inc. – NASDAQ:OTLK - TradingView
Price to earnings forward of Outlook Therapeutics, Inc. – NASDAQ:OTLK - TradingView
Price to earnings forward of Outlook Therapeutics, Inc. – MUN:41O - TradingView
Price to sales forward of Outlook Therapeutics, Inc. – MUN:41O - TradingView
Enterprise value to EBIT forward of Outlook Therapeutics, Inc. – NASDAQ:OTLK - TradingView
OTLK Forecast — Price Target — Prediction for 2027 - TradingView
41O Forecast — Price Target — Prediction for 2027 - TradingView
Outlook Therapeutics Inc (OTLK) Valuation: PE, PB & Fair Value Analysis - TradingKey
Outlook Therapeutics Inc (OTLK) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Price to book forward of Outlook Therapeutics, Inc. – MUN:41O - TradingView
OTLK stock soars 28% after FDA sets July date for Lytenava decision - MSN
OTLK Stock Surges On FDA Lytenava Application Resubmission After Successful Appeal - Stocktwits
Outlook Therapeutics StockWeekly review and sector context for biotech eye drug maker - AD HOC NEWS
Outlook Therapeutics Inc (OTLK) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
One Month, One Drug, One Verdict: Outlook Therapeutics' Lytenava Awaits FDA's Answer on July 29 - AD HOC NEWS
Outlook Therapeutics Heads Into Another FDA PDUFA Decision For Lytenava (NASDAQ:OTLK) - Seeking Alpha
Outlook Therapeutics Secures FDA Class-1 Review for Lytenava, Yet Cash Crunch and European Slowdown - AD HOC NEWS
Outlook Therapeutics’ Lytenava Nears FDA Verdict as Shares Skyrocket — But RSI Flashes Caution - AD HOC NEWS
Outlook Therapeutics Inc (OTLK) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Outlook Therapeutics Inc (OTLK) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
FDA accepts Outlook Therapeutics' resubmitted BLA for ONS-5010 (LYTENAVA) - Ophthalmology Times
OTLK Stock Up 35% as FDA Accepts Resubmitted Eye Drug BLA for Review - The Globe and Mail
Outlook Therapeutics Eye Drug Review Returns To FDA — AgainOutlook Therapeutics (NASDAQ:OTLK) - Benzinga
FDA accepts resubmitted BLA from Outlook Therapeutics - The Pharma Letter
Outlook Therapeutics (OTLK) Gains FDA Acknowledgment for BLA Res - GuruFocus
Outlook Therapeutics (OTLK) Stock After FDA Review Win Is The Valuation Case Already Priced In - Yahoo Finance
Outlook Therapeutics Stock Jumps as FDA Accepts Lytenava BLA, July Decision Looms - TechStock²
1.53%
3.59%
자본화:
|
볼륨(24시간):